NCT05392101View on ClinicalTrials.gov

Low Dose Iron Chelation as TReatment of Oxidative Damage in Sickle Cell Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 20, 2021

Primary Completion Date

August 20, 2022

Study Completion Date

November 20, 2022

Conditions
Sickle Cell Disease
Interventions
DRUG

Deferasirox 360 MG

Deferasirox 360 MG p.o. once daily

Trial Locations (1)

1105 AZ

Amsterdan UMC location AMC, Amsterdam

All Listed Sponsors
lead

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER

NCT05392101 - Low Dose Iron Chelation as TReatment of Oxidative Damage in Sickle Cell Disease | Biotech Hunter | Biotech Hunter